riluzole has been researched along with Atherosclerotic Parkinsonism in 13 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole is a neuroprotective drug used in the treatment of motor neurone disease." | 5.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Riluzole is a neuroprotective drug used in the treatment of motor neurone disease." | 1.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Riluzole, has previously been shown to be protective in animal models of Parkinson's disease in vivo." | 1.31 | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. ( Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S, 2000) |
| "Cotreatment with riluzole (4 mg/kg i." | 1.30 | Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. ( Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F, 1997) |
| "Pretreatment with riluzole (8 mg kg-1, i." | 1.29 | Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo. ( Boireau, A; Doble, A; Dubédat, P; Meunier, M; Miquet, JM, 1994) |
| "Riluzole pretreatment induced a persistent increase in dopamine turnover when compared to MPTP alone." | 1.29 | Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. ( Benazzouz, A; Boireau, A; Boraud, T; Dubédat, P; Gross, C; Stutzmann, JM, 1995) |
| "Riluzole was administered twice 15 min before, and 24 h after, the lesion." | 1.29 | Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. ( Barnéoud, P; Boireau, A; Doble, A; Dubédat, P; Mazadier, M; Miquet, JM; Parmentier, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensimon, G | 1 |
| Ludolph, A | 1 |
| Agid, Y | 1 |
| Vidailhet, M | 1 |
| Payan, C | 1 |
| Leigh, PN | 1 |
| Carbone, M | 1 |
| Duty, S | 1 |
| Rattray, M | 1 |
| Gilgun-Sherki, Y | 1 |
| Melamed, E | 1 |
| Ziv, I | 1 |
| Offen, D | 1 |
| Boireau, A | 6 |
| Dubédat, P | 5 |
| Bordier, F | 2 |
| Peny, C | 1 |
| Miquet, JM | 3 |
| Durand, G | 1 |
| Meunier, M | 2 |
| Doble, A | 3 |
| Benazzouz, A | 1 |
| Boraud, T | 3 |
| Stutzmann, JM | 5 |
| Gross, C | 1 |
| Barnéoud, P | 1 |
| Mazadier, M | 1 |
| Parmentier, S | 1 |
| Palfi, S | 1 |
| Riche, D | 1 |
| Brouillet, E | 1 |
| Guyot, MC | 1 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Peschanski, M | 1 |
| Hantraye, P | 1 |
| Bezard, E | 2 |
| Imbert, C | 1 |
| Gross, CE | 2 |
| Bioulac, B | 1 |
| Imperato, A | 2 |
| Moussaoui, S | 2 |
| Hassani, OK | 1 |
| Mouroux, M | 1 |
| Bohme, GA | 1 |
| Féger, J | 1 |
| Obinu, MC | 1 |
| Reibaud, M | 1 |
| Blanchard, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy[NCT02422485] | Phase 1 | 10 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)[NCT00211224] | Phase 3 | 800 participants | Interventional | 2000-04-30 | Terminated | ||
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy[NCT02460731] | Phase 1 | 6 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies[NCT01056965] | Phase 1 | 12 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticoba[NCT02133846] | Phase 1 | 44 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for riluzole and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
12 other studies available for riluzole and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Excitatory Amino | 2012 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug | 2003 |
Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopami | 1994 |
Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Exc | 1994 |
Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.
Topics: Animals; Antiparkinson Agents; Dopamine; Electromyography; Excitatory Amino Acid Antagonists; Macaca | 1995 |
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Brain Chemistry; Ce | 1996 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; | 1997 |
Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Behavior, Animal; Disease Mo | 1998 |
Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Electr | 2000 |
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2000 |
Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.
Topics: Adrenergic Agents; Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Male; Models, | 2001 |
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2002 |